Mylan (NASDAQ:MYL) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Wednesday.

Several other research firms have also recently commented on MYL. Cowen restated a “hold” rating and set a $31.00 price target on shares of Mylan in a research note on Thursday, August 9th. Wells Fargo & Co reaffirmed a “hold” rating on shares of Mylan in a report on Wednesday, July 25th. Royal Bank of Canada dropped their price objective on Mylan from $51.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, November 6th. Mizuho lowered Mylan from a “buy” rating to a “neutral” rating in a report on Friday, October 5th. Finally, Leerink Swann dropped their price objective on Mylan from $53.00 to $47.00 and set an “outperform” rating on the stock in a report on Thursday, August 9th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $46.56.

Shares of Mylan stock traded down $0.53 during trading hours on Wednesday, hitting $33.38. 3,632,041 shares of the company were exchanged, compared to its average volume of 4,867,245. Mylan has a 1 year low of $30.33 and a 1 year high of $47.82. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.26 and a quick ratio of 0.77. The stock has a market capitalization of $17.84 billion, a PE ratio of 7.32, a price-to-earnings-growth ratio of 1.14 and a beta of 1.53.

Mylan (NASDAQ:MYL) last released its quarterly earnings results on Monday, November 5th. The company reported $1.25 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.19 by $0.06. Mylan had a return on equity of 19.39% and a net margin of 4.71%. The business had revenue of $2.86 billion during the quarter, compared to analysts’ expectations of $2.91 billion. During the same quarter in the prior year, the business earned $1.10 earnings per share. The company’s quarterly revenue was down 4.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Mylan will post 4.66 EPS for the current year.

A number of institutional investors have recently bought and sold shares of MYL. First Mercantile Trust Co. acquired a new stake in Mylan in the second quarter valued at $121,000. Stratos Wealth Partners LTD. acquired a new stake in Mylan in the third quarter valued at $183,000. FTB Advisors Inc. acquired a new stake in Mylan in the second quarter valued at $188,000. Reilly Financial Advisors LLC grew its holdings in Mylan by 69.4% in the third quarter. Reilly Financial Advisors LLC now owns 5,217 shares of the company’s stock valued at $191,000 after purchasing an additional 2,137 shares during the last quarter. Finally, BB&T Corp acquired a new stake in Mylan in the third quarter valued at $202,000. 81.91% of the stock is currently owned by institutional investors.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Recommended Story: Technical Analysis

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with's FREE daily email newsletter.